Method of producing an immunoligand/payload conjugate
AssigneeNbe-Therapeutics AG
InventorsUlf GRAWUNDER, Roger Renzo BEERLI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
Claims24
A method of producing an immunoligand/payload conjugate, which method encompasses conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof.
The method according to any of the aforementioned claims, wherein the immunoligand comprised in the immunoligand/payload conjugate is at least one selected from the group consisting of an antibody, modified antibody format, antibody derivative or fragment, and/or an antibody mimetic.
The method according to any of the aforementioned claims, wherein the immunoligand binds at least one entity selected from the group consisting of
- a receptor
- an antigen
- a growth factor,
- a cytokine, and/or
- a hormone.
The method according to any of the aforementioned claims, wherein at least one catalytic domain of the sequence-specific transpeptidase is fused to the N-terminus or the C-terminus of either the immunoligand or the payload.
The method according according to any of the aforementioned claims, wherein the sequence-specific transpepeptidase is at least one selected from the group consisting of
- a sortase enzyme, or one or more fragments or derivatives thereof
- a split-intein, or one or more fragments or derivatives thereof
The method according to any of the aforementioned claims, wherein the payload comprised in the immunoligand/payload conjugate is at least one selected from the group consisting of
- a marker,
- a processing tag, and/or
- a drug.
The method according to any of the aforementioned claims, wherein said marker is at least one selected from the group consisting of
- a radiolabel, preferably a radioactively labelled peptide or protein
- a fluorescent label, preferably a fluorescent peptide or protein, and/or
- an enzyme label, preferably a peroxidase.
The method according to any of the aforementioned claims, wherein said drug is at least one selected from the group consisting of
- a cytokine
- a radioactive agent
- an anti-inflammatory drug
- a toxin, and/or
- a chemotherapeutic agent
The method according to any of the aforementioned claims, wherein said immunoligand comprises at least two subunits each being conjugated to a payload.
The method according to any of the aforementioned claims, which method allows a stoichiometrically defined relationship between immunoligand and payload.
The method according to any of the aforementioned claims, which method allows a site-specific conjugation of a payload to the immunoligand.
An immunoligand/payload conjugate obtained with a method according to the above claims.
Use of an immunoligand/payload conjugate according to the above mentioned claims for
- in vitro or in vivo diagnosis of a given pathologic condition
- in vitro or in vivo prediction or prognosis with respect to a given pathologic condition
- the treatment of a human or animal subject suffering from or being at risk of developing a given pathologic condition, and/or
- research and/or development purposes
A low molecular-weight payload modified with a Glyn-modification, wherein, n>1, preferably n=3 or n=5.
Dependencies are inferred from the claim text.